The ACS publishes an annual "Cancer Facts & Figures" report, which provides comprehensive statistics on cancer incidence, survival rates, mortality, and trends in the United States. The report typically highlights progress in early detection, advancements in treatment, and disparities in cancer outcomes.
The ACS publishes an annual "Cancer Facts & Figures" report, which provides comprehensive statistics on cancer incidence, survival rates, mortality, and trends in the United States. The report typically highlights progress in early detection, advancements in treatment, and disparities in cancer outcomes. For example, recent statistics have shown that the 5-year cancer survival rate has reached 70%, a significant milestone reflecting decades of improvement in cancer research, early screening, and innovative therapies such as immunotherapy and targeted treatments.
However, underlying challenges persist, including disparities in access to care, variations in survival rates by cancer type, and missed opportunities for early detection. The ACS continues to emphasize the need for equitable and personalized approaches to cancer prevention, treatment, and survivorship care.
Introduction: Circulating tumor DNA (ctDNA) has emerged as a promising noninvasive biomarker for monitoring treatment response and residual disease in solid tumors. However, its prognostic value during neoadjuvant chemotherapy (NAC) for localized pancreatic ductal adenocarcinoma...
Introduction: Aspirin is one of the few interventions proven to reduce colorectal and other Lynch syndrome–associated cancers. The earlier CaPP2 trial established 600 mg daily aspirin as an effective chemopreventive strategy, but concerns regarding long-term...
Introduction: The TOPAZ-1 trial established durvalumab combined with gemcitabine and cisplatin (GemCis) as the first immunotherapy-based first-line standard of care for advanced biliary tract cancer (BTC). However, long-term survival outcomes and durability of benefit beyond...
Introduction: Somatostatin receptor (SSTR) PET/CT has become indispensable for diagnosing, staging, and monitoring neuroendocrine tumors (NETs). However, until now, there has been no standardized method for assessing treatment response using SSTR PET imaging. This international...
Introduction: Staging laparoscopy (SL) is recommended for patients with locally advanced gastric cancer to detect occult peritoneal metastases before curative treatment. However, its real-world utilization across Europe remains uncertain. This large GASTRODATA study evaluated the...
Introduction: Neoadjuvant immune checkpoint inhibitors have transformed the management of mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) locally advanced colorectal cancer, achieving unprecedented pathological response rates. Experimental evidence suggests that cyclooxygenase-2 (COX-2) inhibition may enhance...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.